Organon (OGN) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $1.6 billion, up 5% at constant currency and 4% as-reported, driven by strong growth in women's health, biosimilars, and established brands, with volume gains offsetting price erosion.

• Adjusted EBITDA was $459 million (29% margin), including $51 million in IPR&D and milestone expenses; adjusted diluted EPS was $0.87.

• Net income surged to $359 million, benefiting from a $210 million tax asset valuation allowance release.

• Dermavant acquisition closed, adding VTAMA, a differentiated topical for atopic dermatitis, with significant market potential pending FDA approval.

• Volume growth and new product launches, including Emgality and expanded licensing deals, supported performance despite headwinds in NuvaRing and mature brands.

Financial highlights

• Q3 revenue of $1.582 billion, up 4% year-over-year (5% ex-FX); adjusted gross margin was 61.7%, down from 62.6% last year.

• Non-GAAP adjusted net income was $226 million ($0.87/share), nearly flat year-over-year.

• GAAP net income was $359 million, with diluted EPS of $1.38, reflecting tax benefits.

• Free cash flow before one-time costs for YTD was nearly $700 million; cash and equivalents at $763 million.

• Net leverage ratio improved to ~4.0x as of September 30, 2024.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $6.375–$6.425 billion, with expected constant currency growth of 3.1%–3.8%.

• Adjusted EBITDA margin guidance revised to 30.0%–31.0%, reflecting IPR&D and product mix.

• Adjusted gross margin expected at ~61.5% for 2024; effective non-GAAP tax rate projected at 18.5%–20.5%.

• 2025 expected to see continued constant currency revenue growth, with Dermavant contributing $150 million+.

• One-time spin-related costs expected to be $150 million for the year, minimal in 2025.